BIOPOR Bioporto A/S

BioPorto initiates search for new CFO as Ole Larsen resigns

BioPorto initiates search for new CFO as Ole Larsen resigns

April 26, 2021

Announcement no. 8

BioPorto initiates search for new CFO as Ole Larsen resigns

Having served as Chief Financial Officer (CFO) and member of the management team of BioPorto A/S since 2018, Ole Larsen has today tendered his resignation to pursue other opportunities outside BioPorto.

“It is with regret that we received Ole’s resignation. He has been a truly important asset for BioPorto. During his three-year tenure, he has established a strong performing finance organization while focusing on broadening our investor reach and dialogue which has been pivotal in execution of our funding strategy. I am grateful for his strong contribution and wish him all the best in his future endeavors,” says Peter Mørch Eriksen, CEO of BioPorto.

Ole will leave the Company by the end of May 2021 and remain available for the Company until the end of October 2021.

The search for a successor will be initiated immediately and we will communicate as soon as we have concluded on the search process.

The content of this announcement does not alter BioPorto’s financial guidance for 2021 as most recently presented in the Annual Report for 2020.

Hellerup, April 26, 2021

BioPorto A/S

For further information, please contact:

Peter Mørch Eriksen, CEO BioPorto A/S

Telephone , email

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
26/04/2021

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift me...

BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift med fuld eksekvering af strategiske mål og stærk NGAL-salgsvækst 15. august 2025Meddelelse nr. 19 BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift med fuld eksekvering af strategiske mål og stærk NGAL-salgsvækst. København, Danmark, 15. august 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) offentliggjorde i dag delårsregnskab for andet kvartal 2025 og en forretningsopdatering. Fortsat fremdrift på vigtige strategiske milepæle i 2. kvartal 2025 Fuld realisering af de ...

14h / 50m 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto Interim Result for the Second Quarter of 2025 - Continued pro...

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. August 15, 2025Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen, Denmark, August 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the second quarter of 2025 and a business update. Continued progress on key strategic milestones f...

14h / 50m 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto attends the Association for Diagnostics & Laboratory Medicine...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. July 28, 2025News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. BioPorto is pleased to announce its attendance and the general multiple NGAL and Acute Kidney Injury (AKI) focused elements of the Association for Diagnostics Medicine meeting, this year held in...

July 28, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

June 27, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

June 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch